Accéder au contenu
Merck

Structural basis of receptor recognition by SARS-CoV-2.

Nature (2020-04-01)
Jian Shang, Gang Ye, Ke Shi, Yushun Wan, Chuming Luo, Hideki Aihara, Qibin Geng, Ashley Auerbach, Fang Li
RÉSUMÉ

A novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans, causing COVID-191,2. A key to tackling this pandemic is to understand the receptor recognition mechanism of the virus, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor-angiotensin-converting enzyme 2 (ACE2)-in humans3,4. Here we determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2. In comparison with the SARS-CoV RBD, an ACE2-binding ridge in SARS-CoV-2 RBD has a more compact conformation; moreover, several residue changes in the SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD-ACE2 interface. These structural features of SARS-CoV-2 RBD increase its ACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus that is closely related to SARS-CoV-2, also uses human ACE2 as its receptor. The differences among SARS-CoV-2, SARS-CoV and RaTG13 in ACE2 recognition shed light on the potential animal-to-human transmission of SARS-CoV-2. This study provides guidance for intervention strategies that target receptor recognition by SARS-CoV-2.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (450-469), 95% (HPLC), lyophilized powder
Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (370-394), ≥95% (HPLC), lyophilized powder
Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (480-499), ≥95% (HPLC), lyophilized powder
Sigma-Aldrich
Anti-SARS-COV-2-Spike-RBD region Peroxidase conjugated antibody produced in rabbit